MCA
MRNA icon

McGuire Capital Advisors’s Moderna MRNA Stock Holding History

McGuire Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700 Buy
10
+4
+67% +$207 ﹤0.01% 802
2026
Q1 		$305 Hold
6
– – ﹤0.01% 816
2025
Q4 		$177 Buy
+6
New +$163 ﹤0.01% 907

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

McGuire Capital Advisors's MRNA Position: Q2 2026 in Review

McGuire Capital Advisors increased its Moderna (MRNA) stake by 67% in Q2 2026, buying an estimated $207 and bringing the position to 10 shares worth $700. The position accounts for ﹤0.01% of the portfolio, ranked #802.

McGuire Capital Advisors first reported a position in MRNA in Q4 2025 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • McGuire Capital Advisors held 10 shares of Moderna worth $700 as of Q2 2026.
  • McGuire Capital Advisors bought 4 Moderna shares in Q2 2026, an estimated $207.
  • Moderna made up ﹤0.01% of McGuire Capital Advisors's portfolio in Q2 2026, its #802 holding.
  • McGuire Capital Advisors first reported a position in Moderna in Q4 2025 and has held it in 3 quarters since.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.